Recent Updates
Recently added Catalysts
JSPR Negative Sentiment

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR

Key Takeaway: Jasper Therapeutics, Inc. is involved in a class action lawsuit initiated by the DJS Law Group, claiming violations of securities laws. The lawsuit alleges that the company made misleading statements regarding its operational integrity and third-party manufacturing compliance. These claims suggest that the company's clinical trials may be adversely affected due to these discrepancies. Shareholders who purchased shares between November 30, 2023, and July 3, 2025, are encouraged to participate in recovery processes.
Price reaction · baseline $1.79 (2025-11-17 close) · hit after-hours · clean, no other JSPR news in the window
day 0 close
+2.2%

Market Sentiment Analysis

CONCERNS & RISKS

  • Jasper Therapeutics is facing a class action lawsuit for securities law violations.
  • Claims include that the company made false and misleading statements to the market.
  • Issues with third-party manufacturing partners threaten the integrity of clinical trials.
  • The company's public statements throughout the class period are described as materially misleading.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+18%
120-day peak, hindsight
Typical move
7.8%
average across 5 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
Isradipine
Phase 1 · Nicotine Dependence

Full Press Release Details

LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 30, 2023 to July 3, 2025
DEADLINE: November 18, 2025
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Jasper’s controls over third-party manufacturing was insufficient to ensure its vendors followed all applicable rules and regulations. The Company’s clinical trials were placed at risk due to problems with its manufacturing partners. Based on these facts, Jasper’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Frequently Asked Questions

What is the class action lawsuit against Jasper Therapeutics about?

The lawsuit claims Jasper made false statements regarding its manufacturing controls and clinical trials.

What are the key dates for the Jasper Therapeutics class action?

The class period is from November 30, 2023, to July 3, 2025, with a deadline of November 18, 2025.

How can shareholders participate in the class action lawsuit?

Shareholders who purchased shares during the class period can contact DJS Law Group to register.

Is there a cost to participate in the lawsuit?

There is no cost or obligation for shareholders to participate in the class action case.

What services does DJS Law Group provide?

DJS Law Group focuses on investor return, securities class actions, and corporate governance litigation.

Last updated: Nov 18, 2025